also different in the renal cortex and spleen. Method 3 with the spleen to estimate V ND (or reference SUV) gave the highest non-displaceable uptake and the largest HC vs. T1DM group differences. Significant group differences were also observed in V T (or SUV) with method 1 using spleen. SUV was affected by differences in the input function between groups and between enantiomers.
Introduction
The radiotracer [ 18 F] fluoropropyl-(+)-dihydrotetrabenazine ([ 18 F] FP-(+)-DTBZ) is a positron emission tomography (PET) imaging agent for the vesicular monoamine transporter type 2 (VMAT2). In addition to the brain, VMAT2 is expressed within the pancreas [1] [2] [3] , and its pancreatic distribution strongly correlated and overlapped with the insulin-positive β-cell [4] , with a minor (7-10 %) [4] [5] [6] contribution from VMAT2-positive pancreatic polypeptide (PP) cells. Therefore, [ 18 F]FP-(+)-DTBZ has been evaluated as a possible biomarker to quantify human beta cell mass (BCM). If VMAT2-positive PP cells are not affected by T1DM, the total specific binding of [ 18 F ]FP-(+)-DTBZ in the T1DM group would be only 7-10 % of that in healthy control (HC) group.
[ 18 
F]FP-(+)-DTBZ
shows excellent pancreatic uptake in rodents [7] , baboons [5, 8] , and humans [9, 10] . Additionally, [ 18 F]FP-(+)-DTBZ binding in the pancreas was significantly reduced in patients with type 1 diabetes mellitus (T1DM), compared with HCs. Given that functional BCM in T1DM patients should be nearly depleted, the reduction in [ 18 F ]FP-(+)-DTBZ binding was smaller than might be expected. Since the PET signal is a sum of specific VMAT2 binding in the β-cells, minor specific binding to the PP cells, and non-displaceable uptake (i.e., non-specific binding + free tracer in pancreatic tissue), current PET imaging data suggest that some or all of the signals in T1DM patients were due to non-specific uptake.
To address this hypothesis, the pancreatic nondisplaceable uptake of [ 18 F ]FP-(+)-DTBZ must be known. Non-displaceable uptake in the rodent pancreas was estimated as~20 % of the total by pre-treatment [7] or~40 % by displacement [11] with unlabeled FP-(+)-DTBZ. Nondisplaceable uptake can also be estimated if a suitable reference tissue with minimal specific VMAT2 signal can be defined. Such an ideal reference tissue would have uptake equal to the non-displaceable uptake in the pancreas. From previous baboon studies, it is not clear if such an ideal reference exists.
Non-displaceable distribution volume (V ND ) in baboons was assessed with active (+)-and inactive (−)-enantiomers of [ 18 F]FP-DTBZ [5, 8] , taking advantage of the large differences in stereospecific affinity, i.e., K i of 9 3000 nM for the (−)-enantiomer vs. 0.1 nM for the (+)-enantiomer [12] . For simplification, the distribution volumes (V T ) of [ 18 [8] , suggesting that pancreatic V ND (+) could be estimated by V T (+) of the renal cortex or spleen. In contrast, our study showed that the V T (+) values of the renal cortex and spleen differed and were higher than the V T (−) of the pancreas by 125 % (renal cortex) and 30 % (spleen) [5] . In addition, V T (−) values among the pancreas, renal cortex, and spleen differed, indicating that non-specific uptake was different among the organs, and there was no ideal reference tissue. We therefore assessed three methods to define pancreatic V ND : (1) V T (+) in the renal cortex or spleen, (2) V T (−) in the pancreas, and (3) a scaled V T (+) in the renal cortex or spleen [5] . We also evaluated the presence of tissue radiometabolites with an ex vivo study [5] in baboons and showed that radiometabolites in the spleen and pancreas were low (6 and~1 %, respectively) but were more dominant in the renal cortex (30 %). Thus, the spleen was regarded as a more favorable candidate for a pseudoreference tissue.
In this study, we extended our baboon work and conducted PET studies of [ 18 
Materials and Methods

Human Subjects
Six HC subjects (20-35 years; five males and one female; 85.9 ± 8.8 kg; BMI = 27.2 ± 8.8 kg/m 2 ) and four T1DM patients (28-36 years; three males and one female; 77.2 ± 6.7 kg; BMI = 25.8 ± 1.0 kg/m 2 ; duration of diabetes = 12-29 years; C-peptide G 0.1 ng/ml; insulin dose (n = 2) = 30-40 U/day) were recruited for this study. The BMI of the HC group was more variable than that of the T1DM group. Each subject was scanned twice on different days, after injection of either [ 18 
Arterial Input Function Measurement
For the first 7 min of each study, arterial blood was continuously counted for radioactivity using an automated system (PBS-101; Veenstra Instruments, Joure, The Netherlands). Discrete blood samples were manually drawn at 3, 5, 7, 15, 20, 30, 45, 60, 75, 90 , and 120 min. Samples were centrifuged to obtain plasma, and then whole blood and plasma samples were counted with a calibrated well counter.
Analysis of the parent and its metabolites in the plasma by HPLC and measurement of plasma free fraction (f P ) of the radiotracers were conducted following procedures described before [5] .
PET Imaging and Image Processing
For most scans, the radiotracer was administered over 1 min by an infusion pump. Four subjects (one HC and three T1DM) had previously been scanned with [
18 F]FP-(+)-DTBZ using bolus plus constant infusion (B/I) (K bol = 360 min), and their B/I PET data were converted to bolus data using the Eq. 5B in [13] , in order to compare the standard uptake values (SUVs) obtained using different tracer injection protocols. PET images were acquired for 2 h using a Biograph mCT PET/x-ray computed tomography (CT) scanner (Siemens Medical Solutions, Knoxville, TN). Dynamic data were reconstructed with the ordered subset expectation maximization algorithm with point spread function correction using time-of-flight measurements. Frame timing was 6 × 30 s, 3 × 1 min, 2 × 2 min, and 22 × 5 min.
PET images were corrected for motion using a mutual information algorithm (BioImage Suite, version 3.01, www.bioimagesuite.com) and registered to a movingaverage reference image. The first reference image was obtained by summing the first 10 min of data (initial frame subset), and the next frame was realigned to this reference image. Then, the subset used to compute the reference image was updated by replacing the first frame with the motioncorrected frame. This process was repeated over the whole dataset.
Computation of Regional Time-Activity Curves
Regions of interest (ROIs) of the pancreas, renal cortex, and spleen were manually delineated on multiple slices of the summed (0-90 min post injection) motion-corrected images. To minimize partial volume and respiratory motion effects, the ROIs were thinned using the classical thinning algorithm [14] and skeletonized to one voxel (2 mm) thickness. Typical examples of ROIs are shown in Fig. S1 (supplemental material). The algorithm uses morphological image processing, preserving the topology (extent and connectivity) of the original ROI. The final ROIs were applied to generate time-activity curves (TACs).
Kinetic Modeling and Non-displaceable Distribution Volume Estimation
Outcome measures were derived with kinetic analysis of the TACs using the metabolite-corrected input function. The one-and two-tissue compartment (1TC, 2TC) models and the multilinear analysis 1 (MA1) method (t* = 40 min) [15] were applied to calculate the distribution volume (V T ) [16] . The MA1 method uses the arterial input function to calculate two parameters, V T and b (constant value after an equilibration time, t*). The renal cortex and spleen have been proposed as reference tissue candidates, and our baboon displacement study suggested that these regions lack specific binding [5] . Assuming that [ 18 Methods 1 and 3 were also assessed using the renal cortex as a reference tissue. Using each method to derive V ND , BP ND was determined as V T /V ND − 1, and the group difference between the HC and T1DM was assessed.
Assessment of Standardized Uptake Value
SUVs were computed over the time window, 60-120 min. The B/I PET data were converted to bolus values for SUV computation (see BDiscussion^for details). The pancreas and spleen TACs of T1DM patients before and after conversion are shown in the supplementary material (Fig. S2) . The SUV ratio (SUVR), the ratio of SUV in the pancreas to that in the reference tissue, was determined with the reference SUV calculated using methods 1 and 3. The group differences of SUV and SUVR were compared with those of V T and BP ND to investigate the potential use of SUV and SUVR.
Statistical Analysis
Outcome measures were compared between HC and T1DM groups using two-tailed Student's t test and two-tailed nonparametric test (Mann-Whitney test and Wilcoxon matchedpairs signed-rank test). Since P values were similar between parametric and non-parametric tests and significance (P G 0.05) did not change between the tests, parametric test results are shown in the BResults.^All modeling was performed with in-house programs written with IDL 8.0 (ITT Visual Information Solutions, Boulder, CO).
Results
Human Injection and Scan Parameters
Injection parameters are summarized in Table 1 . The injected mass and specific activity did not differ between the scans with [ Figure 1 shows the unmetabolized fractions for [ 18 
Plasma Analysis
Uptake of the Enantiomers
Kinetic Model Assessment
For both enantiomers, the quality of curve fitting was similarly good with the 2TC and MA1 models (Fig. 4) , while a moderate lack of fit was seen with the 1TC model. The 2TC V T estimates were not always stable (V T 9 1000 ml/ cm 3 , relative standard error 9 10 %; unstable results in1 5 % of all fits). Using the 2TC values as a gold standard (excluding unstable estimates), the 1TC V T values showed substantially underestimation for [ 18 Given the good quality of fit, estimation with good stability, and moderate underestimation, the MA1 model was chosen as the model to compute V T values. Table 2 and Fig. 5 show V T values and SUVs from 60 to 120 min post injection. For both radiotracers, V T and SUVs were highest in the pancreas. For [ 18 F ]FP-(+)-DTBZ, V T and SUVs in the spleen were higher than those in the renal cortex (V T : P = 0.032 (HC), P = 0.004 (T1DM); SUV: P = 0.018 (HC), P = 0.086 (T1DM)). For [ 18 F ]FP-(−)-DTBZ, V T and SUVs in the spleen were similar to those in the renal cortex (V T : P = 0.19 (HC), P = 0.46 (T1DM); SUV: P = 0.18 (HC), P = 0.47 (T1DM)). Blood volume correction was not included in the above modeling. To assess if this correction was necessary, the 1TC and 2TC models with blood volume correction were also applied to the TACs. For the renal cortex, the fitted blood volume value was implausible (9 100 %) in most scans regardless of the model. Using the 1TC model, the fitted blood volume values differed greatly among scans in the pancreas (0~113 % for [ 18 (Tables S1 and S2 ). The estimated distribution volumes were reduced by a small amount (a reduction of 0-2 ml/cm 3 ). The delay between the plasma input curve and tissue time-activity curves was not taken into account in the modeling. It is expected that the delay has a negligible effect on V T values. To investigate the effect of delay, we computed the V T values using the MA1 model with delay. The delay was estimated by applying the 1TC model to the first 10-min whole-body TAC. As expected, the V T values did not change (V T (MA1 with delay) = 0.99 × V T (MA1 without delay) + 0.08, R 2 = 1.00). V T (+) and SUV(+) values in the pancreas were also compared between HC and T1DM groups. As expected, a significant group difference was found (V T : P = 0.04; SUV: P = 0.002) with differences of 42 % for V T and 56 % for SUV. SUV(−) values in the pancreas were significantly higher in the HC than in the T1DM group, and at least some of these differences were attributed to input function effects (see BDiscussion^). SUV(+) and SUV(−) values in the renal cortex and spleen were also higher in the HC than in the T1DM group, but the difference was not significant. V T (−) values in the pancreas were higher in the HC, but this difference was not significant. The V T (+) and V T (−) values in the renal cortex and spleen did not show group differences. Table 3 summarizes the V ND and pancreatic BP ND estimates using the three methods with two different reference tissues. In method 1, which uses the reference tissue V T (+) values, a significant group difference was found (P = 0.01) in pancreas BP ND with the spleen reference, but not with the renal reference. Method 2 used pancreatic V T (−) as V ND , and since this value was similar to or lower than V T (+) in the renal cortex or spleen, method 2 gave similar or higher BP ND values compared to method 1. Additionally, the group difference in BP ND using method 2 was smallest among all methods. For method 3, which accounts for the inter-organ differences in V T (−) by scaling the V T (+) values in the reference tissues, the scale factor (α) was not significantly different between HC and T1DM groups. Therefore, the whole population value (α) was used to calculate V ND (+). Pancreatic BP ND using method 3 was smaller than that from The reference SUV and SUVR-1 values are summarized in Table 4 (SUVR-1 is shown to be compatible with BP ND ). Overall, the results showed similar patterns to the V ND and BP ND estimates. Significant group differences were found in methods 1 and 3, with the spleen as a reference tissue, and the P values were smaller when SUVR, rather than BP ND , was used. The largest group difference was found in method 3 with α spleen . We selected methods 1 and 3 with the spleen as a reference tissue for normalization.
Non-displaceable Binding Estimation
Discussion
PET studies were conducted with two radiolabeled enantiomers, [ 18 To compute the SUV obtained using different tracer injection protocols (B/I and bolus), the B/I PET data were converted to bolus data using the equation in [13] . Since the biological system is linear at tracer doses, the B/I response can be determined from the response function of a bolus injection, and the B/I SUVs can be accurately corrected to the bolus SUVs. This process accounts for the fact that the unmetabolized fraction from the B/I PET data will be higher than that from the bolus PET data. Kinetic parameters other than SUV are not affected by the difference in the injection protocols.
Active and inactive enantiomers of [ 11 C]DTBZ have been used to measure non-displaceable uptake and to assess VMAT2-specific binding in the human brain [19] . The distribution of [ 11 C](−)-DTBZ was moderately uniform across the brain. However, it was not clear yet whether 18 18 18 ]FP-DTBZ can be used to measure pancreatic non-displaceable uptake and assess whether non-displaceable uptake is uniform across organs. A baboon study by Harris et al. [8] reported the pancreatic V T (−) was similar to V T (+) in both the spleen and kidney, indicating that the spleen and kidney might be suitable reference tissues. However, we found heterogeneous V T (−) among organs in baboons [5] , suggesting the absence of an ideal reference tissue in non-human primates [5] .
F-FP-(-)-DTBZ (T1DM)
F-FP-(+)-DTBZ (T1DM)
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Comparing V T values between baboons [5] and humans, pancreas V T (+) and V T (−) and spleen V T (+) were similar. While V T (−) was highest in the renal cortex in baboon, it was lowest in human. While spleen V T (−) was slightly lower than pancreas V T (−) in baboon, spleen V T (−) was substantially lower than pancreas V T (−) and at a similar level to renal cortex V T (−) in human. In addition to species differences in parent tracer uptake, differences between baboon and human might be attributed to the difference in types of labeled metabolites and metabolite fraction in tissues. From ex vivo baboon studies, the metabolite fraction at 90 min post injection of [ 18 F]FP-(−)-DTBZ was 95 % in the plasma, 70 % in the renal cortex, 50 % in the spleen, and 40 % in the pancreas. The metabolite fraction in the plasma was lower (70 %) in human. However, the metabolite fractions in human organs cannot be measured.
We applied the kinetic models with and without blood volume correction to the TACs. Even though the blood volume fraction was large (up to 63 % in the spleen), a small reduction was observed in V T with blood volume correction. V T values were derived from the MA1 model, and SUVs were calculated from 60 to 120 min post injection. Values are expressed as mean ± SD for healthy controls (HC, n = 6) and T1DM patients (n = 4). Group differences were tested using the t test Naganawa M. et al.: Enantiomers of [ 18 under equilibrium condition, i.e., the concentration ratio of tissue to metabolite-corrected plasma. For example, the spleen V T with blood volume correction is described as {C tissue − blood volume × C whole blood } / {parent fraction × C plasma, unc }, where Bunc^refers to the plasma concentration uncorrected for metabolites. Since C whole blood and C plasma, unc were similar at later times post injection, the V T in the spleen is {C tissue − 0.63 × C plasma, unc } / {0.3 × C plasma, unc } = V T (spleen, without blood volume correction) − 2.1 (here, 0.3 represents the parent plasma fraction). Thus, the difference with/without blood volume correction is estimated as~2 ml/cm 3 . The differences would be smaller in tissues with smaller blood volume.
In addition to the high affinity of [ [20] . The affinity for 44 other CNS and cardiovascular receptors was found to be even lower (IC 50 9 10 μM) [20] . [ V ND values and α ratios were derived from the MA1 V T values using three methods. See text for details. Data are expressed as mean (COV%). Group differences in pancreatic BP ND were compared using t test *α spleen and α renal from all subjects were used to calculate V ND and BP ND sigma-1 receptors (K i = 110 nM), which is similar to that of [ [7] , negligible changes were detected in SUV curves in the pancreas, renal cortex, and spleen. Hence, the results indicate the low-affinity sigma-1 receptor binding does not contribute to the binding in the renal cortex and spleen. Extrapolating from the results in baboons, it is expected that [ We addressed two questions to quantify specific binding in the pancreas: (1) is non-displaceable uptake homogeneous among organs and (2) is non-displaceable uptake similar between enantiomers. For the first question, if nondisplaceable uptake is uniform among organs, V T (−) values of different organs are expected to be similar. However, V T (−) in the pancreas was significantly higher than that in the spleen and renal cortex, so V T (−) was not uniform among organs. Considering that tissue compositions including the blood volume contributions are different between organs, this is not a surprising result. For example, even if the uptake per unit extravascular volume is compatible in different organs, since the blood volumes differ substantially between organs (see above), V ND values will differ. Therefore, it is not possible to directly select a reference tissue with the same non-displaceable uptake as the pancreas. For the second question, since VMAT2 density is considered to be negligible in the renal cortex and spleen, V T (−) was expected to be similar to V T (+) in these regions. However, V T (−) was significantly lower than V T (+) in the renal cortex and spleen (for both regions, HC: P G 0.001, T1DM: P G 0.01), while V T (−) of the spleen was similar to that of the renal cortex. This suggests that non-displaceable uptake in tissue is different between [ Note that the plasma free fractions of the enantiomers were also substantially different; i.e., they interact differently with proteins, so it is not surprising that nonspecific binding in tissue differs. Based on these results, non-displaceable uptake is different among organs and between the two enantiomers.
Since no ideal reference tissue exists, we explored normalization methods to compare VMAT2 binding between HC and T1DM groups. We applied three methods based on the baboon study [5] . The first method is a conventional one used in previous [ 18 F ]FP-(+)-DTBZ studies. It assumes that V ND (+) is uniform among organs and used V T (+) (or SUV(+)) of either the spleen or renal cortex as V ND (+) (or reference SUV(+)). Since V T (+,spleen) was higher than V T (+,renal cortex) in both HC and T1DM groups (Table 2) , pancreatic BP ND (ref:spleen) was lower than pancreatic BP ND (ref:renal cortex). A significant difference in BP ND between groups was observed with the spleen as a reference, but the difference in this small cohort was not statistically significant with the renal cortex as a reference. A significant difference in SUVR-1 was also observed only when the spleen was used as a reference. While this method is simple to apply, the inter-organ differences in V T (−) call the assumption of method 1 into question.
The second method assumes uniform non-displaceable uptake of the two enantiomers and the use of pancreas V T (−) as V ND (+). However, this approach requires PET imaging with both enantiomers for each subject. The group differences in BP ND were not significant, and the between-group difference was smallest among the three methods. Furthermore, this second method is not applicable to SUV, since the input function of [ 18 F] FP-(+)-DTBZ was lower than that of [ 18 F]FP-(−)-DTBZ in both HC and T1DM groups (Fig. 2) . Since SUV is affected by plasma clearance, we cannot simply use pancreas SUV(−) as a reference SUV to compare with pancreas SUV(+). Thus, the second method is not recommended.
For the third method, we hypothesized that the betweenorgan ratio (α) of V ND is the same between enantiomers. In We also hypothesized that any radiometabolite contribution to the V ND ratio is similar for both enantiomers. This is important since the plasma metabolite profiles of the two enantiomers were different (Fig. 1) . In plasma, since radiometabolites were measured, a corrected input function was used in the modeling; thus, these differences in metabolites do not affect the V ND values. In tissue, if the fraction of counts attributable to radiolabeled metabolites differed between the enantiomers in a given organ, our assumption would be incorrect. We have no data for tissue radiometabolite fraction in humans; however, we performed such measurements in non-human primate. Specifically, the tissue metabolite fractions in the pancreas and spleen were similar for both enantiomers ([ 18 Table 5 in [5] . The presence of radiolabeled metabolites in the tissue would cause an overestimation of the volume of distribution (the equilibrium ratios of tissue to plasma), with the magnitude of this effect based on the tissue metabolite fraction. Since we found that both (+)-and (−)-tracers had equal radiometabolite fractions in the pancreas and spleen, the overestimation of V ND would be expected to be comparable for both tissues, and this effect would cancel out in calculating the between-organ V ND ratio, α.
The third method is applicable to SUV, and the population ratio calculated from SUV was similar to that from V T . Since we used a population ratio, P values for group differences from method 3 were exactly the same as those from method 1 (Table 4) . However, the between-group difference in pancreas BP ND was the largest of all methods. The use of scaled V T (+,spleen) produced the largest group difference (75 % for BP ND ; 85 % for SUVR-1) and the smallest magnitude of pancreas BP ND and SUVR-1 in T1DM (0.40 for BP ND ; 0.18 for SUVR-1). Such low specific binding in the T1DM pancreas is consistent with the fact that functional BCM is almost completely depleted in T1DM patients. Comparing these results, method 3 with the spleen as a reference tissue was chosen as the suitable normalizing method.
Total tracer uptake in the pancreas (functional binding capacity, FBC) can be computed by multiplying BP ND by the whole pancreas volume [9, 10, 21] . The population values of the pancreas were used for computation (HC 77.77 ml and T1DM 41.16 ml) [22] . Among all methods, method 3 with the spleen as a reference region gave the largest loss (87 %) of FBC in the T1DM group. The remaining 13 % FBC can be partly attributed to VMAT2 binding in the PP cells. This difference between groups is similar to the VMAT2-positive PP cell binding (7-10 %).
We also compared the use of pancreas V T (+) or SUV(+) to differentiate the two groups (Table 2) . SUV(+) provided a smaller P value and bigger group differences than V T (+). This larger signal can be attributed to the fact that SUV reflects differences in the input function as well as differences in specific binding between groups. The HC input function was higher than that of T1DM (Fig. 2) for both enantiomers. Moreover, a significant group difference was observed in pancreas SUV(−), which is also affected by the between-group differences in plasma SUV. Since V T (+) can account for the differences in the arterial input, pancreas V T (+) is a more suitable parameter than SUV to differentiate groups, though a larger sample size is needed before completely excluding the utility of SUVs.
There was a trend towards lower pancreas V T (−) in the T1DM group than in the HC group; this was not seen in the spleen or renal cortex. If non-specific binding is lower in the pancreas of T1DM patients, but not in the reference regions, this would cause an underestimation of BP ND in the T1DM patients relative to HC. To quantitatively assess the potential impact of group difference in non-specific binding, we recalculated BP ND with method 3 (spleen) using the group-averaged values of α spleen . In that case, the difference in BP ND between HC and T1DM groups was reduced from 75 % (Table 3) to 42 %. To definitively address this issue, a larger cohort of patients would be needed.
Using the proposed method 3, BP ND values are globally lower than those of previous publications using the kidney [9] or spleen [10] as a reference region, both in HC and T1DM groups. However, the reduction in BP ND and FBC between HC and T1DM groups is now larger than that in previous publications. This larger reduction is more consistent with expectations, since T1DM patients have almost no remaining pancreatic beta cells. However, even with the larger percent reduction in BP ND , the statistical significance of the between-group difference was not altered; this occurred because a single population value of α was used in computing V ND (+).
Conclusions
We compared the kinetics of [ 18 F ]FP-(+)-DTBZ and [ 18 F ]FP-(−)-DTBZ in healthy controls and type 1 diabetes mellitus subjects. The heterogeneity in distribution volumes and SUVs among organs and between enantiomers demonstrated that there is a need to scale uptake values from other organs to provide accurate estimates of nondisplaceable uptake for quantification of VMAT2 in the pancreas. Moreover, SUV is affected by the differences in the plasma clearance between groups, and its use as quantitative outcome measures can thus be misleading. We conclude that BP ND computed using scaled spleen values for non-displaceable uptake is a suitable method for quantification of VMAT2 binding in the pancreas. 
